Pfizer: Integrin beta-6 (IB6) Sigvotatug Vedotin (SV) Translational and Pre-Clinical Research

About and Services

20/03/2025

Pfizer: Integrin beta-6 (IB6) Sigvotatug Vedotin (SV) Translational and Pre-Clinical Research

Description:

To support non-interventional Investigator Sponsored Research projects that will advance the understanding of IB6 patterns of expression and clinical outcomes in NSCLC or explore sigvotatug vedotin’s preclinical activity.

Funding: $200K for 18 months

https://cdn.pfizer.com/pfizercom/2025-01/GMG-2025-ONC-Global-IB6TranslationalPreclinical-RES-final.pdf?VersionId=zvcR0YkUuAxQHrRuunIGK4tRvFk8n2W9

Fields :

Life Sciences

Source :

Foreign